• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Impax settles ‘fax-blasting’ class action suit over EpiPen alternative

September 7, 2017 By Sarah Faulkner

Impax LaboratoriesImpax Laboratories (NSDQ:IPXL) will pony up $4.8 million to settle claims that it sent blasts of unsolicited faxes to Family Medicine Pharmacy advertising its epinephrine auto-injector, according to a document filed in a Alabama federal court this week.

The Alabama-based pharmacy filed the proposed class action suit against Impax in January, alleging that the pharmaceutical company was sending unsolicited faxes advertising its EpiPen alternative without any option to opt out and occupying the use of their fax machines.

Family Medicine Pharmacy claimed that Impax’s behavior violated the Junk Fax Prevention Act, which was signed into federal law in 2005. The law requires senders of fax advertisements to include contact information and notice on the fax that allows recipients to opt out of future fax transmissions. It also states that senders must honor opt-out requests within a 30-day period.

The pharmacy also notes in its original complaint, which was filed in the Alabama Southern District Court under judge William Steele, that the two parties did not have an existing business relationship when Impax alleging inundated its offices with ads.

Impax’s emergency allergy injection product, AdrenaClick, is similar to Mylan‘s (NSDQ:MYL) EpiPen, although regulators do not consider the 2 devices to be exactly the same.

In January, CVS Health Corp. (NYSE:CVS) announced that it will start selling a cheaper, generic version of Adrenaclick.

The Adrenaclick has a list price of more than $400, but the generic is available at all CVS pharmacy locations for both insured and uninsured patients at a cash price of $109.99.

Impax’s device needs to be assembled by hand, unlike Mylan’s EpiPen. The EpiPen 2-pack has a list price of $649.99, according to Reuters, while Mylan’s newly-launched generic rings in at $339.99

Early last month, the largest pharmacy benefit manager in the U.S., Express Scripts (NSDQ:ESRX), said that it would include Mylan’s EpiPen on its 2018 formulary, favoring the drugmaker’s product over auto-injectors from competitors like Impax and Kaleo.

Express Scripts has practiced excluding certain medicines from its list of covered drugs since 2014, pointing towards the high prices taken on by health insurers.

See the best minds in medtech live at DeviceTalks Boston on Oct. 2. 

Filed Under: Drug-Device Combinations, Featured, Legal News, Pharmaceuticals, Wall Street Beat Tagged With: Impax Laboratories, Kaleo Inc, Mylan

IN CASE YOU MISSED IT

  • Omnipod 5 rollout for type 2 rolls on as Insulet pursues next-gen automation
  • LifePlus reports clinical validation of non-invasive glucose, blood pressure monitor
  • Abbott Diabetes head talks Medtronic partnership, exciting times ahead
  • PharmaSens, SiBionics innovatively combine tech in all-in-one insulin patch pump
  • Study backs Biolinq intradermal sensor in muscle loss prevention during GLP-1 therapy

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS